MMF

MMF is the world’s first and only powdered milk fortifier made from human breast milk. It meets the European Society for Paediatric Gastroenterology Hepatology and Nutrition’s (ESPGHAN) guidelines on energy and protein content. As per 2017 WHO Recommendations on newborn health, very low birth weight infants who fail to gain weight, despite adequate breast-milk feeding, should be given fortifiers, preferably those that are human milk based.

Our products are designed to meet the unique nutritional demands of premature babies.

Our products are designed to meet the unique nutritional demands of premature babies and are designed for use in a hospital setting.

Mother’s own breast milk is the first choice for all neonates including premature infants, due to its nutritional composition and immunologic advantages. Please refer to Clinical Evidence tab on our website. In cases where mothers are unable to breastfeed, pasteurised donor human milk is considered by both the British Association of Perinatal Medicine and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition as the best alternative.

Some clinical studies have shown that a purely human milk diet offers protection against, and can decrease the likelihood of, necrotizing enterocolitis (NEC) .

In conjunction with UK hospitals and research organisations NeoKare is conducting clinical studies to demonstrate the benefit / critical role human milk products and fortifiers play in supporting the nutrition requirements of premature babies, for whom mother’s own or donor milk does not provide sufficient nutrition

Our patented technology uses molecular sieving to ensure our MMF (Mother’s Milk Fortifier) meets ESPGHAN guidelines on energy content, protein content and osmolarity, and includes human milk oligosaccharides and antibodies.

NeoKare MMF is the only powder human milk fortifier that has been made from human milk. Some clinical studies have shown that a purely human milk diet offers protection against, and can decrease the likelihood of, necrotizing enterocolitis (NEC).

  • The WHO Technical review in 2006 noted that pasteurisation destroyed HIV, CMV and HTLV. The mothers are serologically tested before their milk is accepted.
  • The EMBA and NICE guidelines support pasteurisation.
  • No peer-reviewed published studies have found the presence of SARS-CoV-2 in milk samples from COVID-19 positive mothers. It is highly unusual for a CoV or other respiratory virus to cross into breast milk.3

    NeoKare has established a UK pharmaceutical grade manufacturing facility in Worcestershire that is fully compliant with the all the relevant standards and guidelines of the Food Standards Authority and relevant industry bodies.

  • The company’s pasteurisers are compliant with FDA requirements.
  • NeoKare uses Holder pasteurisation which is consistent with WHO and NICE recommendations.
  • The company stringently follows all guidelines of NICE (UK) donor screening , Good Manufacturing Practices (GMP), product traceability and Hazard Analysis Critical Control Point (HACCP) for the processing in our manufacturing operation.

Maintaining the health and nutritional needs of both the provider mother’s infants and recipient babies, is the company’s top priority. Our milk collection procedures are aligned with NICE guidelines (CG93). All mums who provide their excess milk are rigorously screened and continuous support is provided throughout the process to ensure their own infant’s needs are met.